icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
" In view of :
- the efficacy and safety data versus placebo,
- the absence of direct comparative data versus other anti-ANF agents, particularly infliximab,
the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies."
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
4qM9DwK7qe5GqqET